首页> Cancers> Daratumumab May Attenuate Cardiac Dysfunction Related to Carfilzomib in Patients with Relapsed/Refractory Multiple Myeloma: A Prospective Study.

Daratumumab May Attenuate Cardiac Dysfunction Related to Carfilzomib in Patients with Relapsed/Refractory Multiple Myeloma: A Prospective Study.

导出 OA

翻译打印收藏纠错

第一作者： Evangelos,Terpos

第一单位： Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, 11528 Athens, Greece.

作者： Evangelos,Terpos ^[1] ; Kimon,Stamatelopoulos ^[1] ; Nikolaos,Makris ^[1] ; Georgios,Georgiopoulos ^[2] ; Ioannis,Ntanasis-Stathopoulos ^[1] ; Maria,Gavriatopoulou ^[1] ; Ageliki,Laina ^[1] ; Evangelos,Eleutherakis-Papaiakovou ^[1] ; Despina,Fotiou ^[1] ; Nikolaos,Kanellias ^[1] ; Panagiotis,Malandrakis ^[1] ; Dimitris,Delialis ^[1] ; Ioanna,Andreadou ^[3] ; Efstathios,Kastritis ^[1] ; Meletios A,Dimopoulos ^[1]

作者单位： Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, 11528 Athens, Greece. ^[1] Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, 11528 Athens, Greece.;Fondazione Toscana Gabriele Monasterio, 56124 Pisa, Italy. ^[2] Laboratory of Pharmacology, Faculty of Pharmacy, National and Kapodistrian University of Athens, 15771 Athens, Greece. ^[3]

关键词 cardiovascular carfilzomib daratumumab heart multiple myeloma toxicity

DOI 10.3390/cancers13205057

PMID 34680206

发布时间 2021-10-26

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交